Xeroderma pigmentosum (XP) is a rare autosomal recessive genodermatosis associated with hypersensitivity to ultraviolet light due to defects in Deoxyribonucleic acid (DNA) repair. These patients have more than a 1000-fold increased risk of developing skin cancers. Although multiple cutaneous malignancies are common, the simultaneous occurrence of angiosarcoma and basal cell carcinoma is a rare phenomenon. We report a case of a 25-year-old male with XP with angiosarcoma scalp and basal cell carcinoma of face and occiput and discuss the treatment of this aggressive neoplasm with a review of the literature pertaining to it.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439790 | PMC |
http://dx.doi.org/10.4103/0971-5851.99753 | DOI Listing |
Cancer Sci
January 2025
Department of Dermatology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Angiosarcoma (AS) is a rare, aggressive malignancy originating from vascular or lymphatic endothelial cells. Despite its severity, little is known about its epidemiology, and no geographical regions have previously been identified as having an exceptionally high incidence. We retrospectively analyzed medical records spanning 37 years (1987-2023) in Okinawa, Japan, identifying 135 cases of AS that were used to calculate its incidence.
View Article and Find Full Text PDFJ Craniofac Surg
December 2024
Division of Neurosurgery, Department of Surgery.
Cutaneous angiosarcoma is a rare and aggressive malignancy originating from endothelial cells lining blood vessels in the skin. The authors present a comprehensive case report of cutaneous angiosarcoma with infiltration of the scalp and skull, with an abnormal presentation highlighting the clinical features, diagnostic challenges, treatment and surgical strategies, and outcomes. The case underscores the complexity of managing this aggressive disease involving critical anatomical structures and emphasizes the need for a multidisciplinary approach to optimal patient care.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2024
Department of Dermatology, University of Illinois College of Medicine, Chicago, IL, USA.
Background: While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. The purpose of this review is to summarize and interpret the literature surrounding the off-label uses of IL-23 inhibitors in dermatologic practice.
Methods: We conducted searches on PubMed and for clinical trials, observational studies, case series, and case reports assessing use of the three IL-23 inhibitors for non-psoriatic dermatologic conditions.
Geriatr Gerontol Int
January 2025
Department of Radiology, Akita University Graduate School of Medicine, Akita, Japan.
J Cutan Pathol
February 2025
Department of Pathology and Dermatology, Virginia Commonwealth University Health System, Richmond, Virginia, USA.
While most forms of alopecia neoplastica are attributable to cutaneous metastases from visceral primary malignancies, rarely a diffuse primary skin cancer may present as alopecia. Herein, we present a case of angiosarcoma which clinically mimicked an inflammatory alopecia and was diagnosed by examination of alopecia-protocol horizontal histologic sections. A 72-year-old female presented to her dermatologist with a chief complaint of hair loss and pruritus.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!